• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Citius Pharmaceuticals, Inc. - Common Stock (NQ:CTXR)

0.9176 -0.0624 (-6.37%)
Streaming Delayed Price Updated: 3:03 PM EST, Jan 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Citius Pharmaceuticals, Inc. - Common Stock

Citius Pharmaceuticals (NASDAQ: CTXR) Eyes $400M Market Opportunity with LYMPHIR Launch
October 16, 2025
Via AB Newswire
Topics Economy
News headline image
Biotech Stocks Race Towards Solutions for Cutaneous T-Cell Lymphoma (CTCL)
July 18, 2024
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - July 18, 2024) - Investorideas.com, a go-to investing platform releases the second... 
Via Newsfile
News headline image
Analysts Hunt for Undervalued Biotech Stocks
July 17, 2024
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - July 17, 2024) - Investorideas.com, a go-to investing platform releases the first... 
Via Newsfile
Topics Economy Initial Public Offering
Citius Pharmaceuticals (CTXR) Eyes Breakthrough with Late-Stage Drug Pipeline Poised for Regulatory Approval
July 17, 2024
Via AB Newswire
Citius Pharmaceuticals (NASDAQ: CTXR) Spearheads the Global Cancer Immunotherapy Market
May 07, 2022
Via Get News
News headline image
Bloodstream Infections - From Threats to Solutions
July 11, 2024
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - July 11, 2024) - Investorideas.com, a go-to investing platform releases the second... 
Via Newsfile
Topics Death
Citius Pharmaceuticals (CTXR) Nears Key FDA Decisions and Launch Plans for 2024
July 11, 2024
Via AB Newswire
News headline image
Biopharma Stocks Transformative Innovation for the Future of Health
July 11, 2024
Vancouver, Kelowna and Delta, British Columbia--(Newsfile Corp. - July 11, 2024) - Investorideas.com, a go-to investing platform releases the first... 
Via Newsfile
Topics Artificial Intelligence
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) Featured in Coverage of the EF Hutton Annual Global Conference
May 16, 2024
Via Investor Brand Network
News headline image
Sidoti Events, LLC’s Virtual November Micro-Cap Conference
November 14, 2023
Via ACCESSWIRE
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) is Specializing in Stem Cell Therapy & Critical Cancer Care Immunotherapy
May 11, 2022
Via Get News
Citius Pharmaceuticals, Inc is helping Global Cancer Immunotherapy to reach the Market Cap of 152 Billion by 2024.
May 04, 2022
Via AB Newswire
Biotechs Zero in on Growing Ovarian Cancer Market as Pivotal Trials Advance Through Regulatory Agencies
May 03, 2021
Via FinancialNewsMedia
Topics Death
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap